RxDoctor Payments Data

Hiren Joshi, MD

Nephrology · Tallahassee, FLNPI 1316268469

Payments from drug & device makers

$1,907in general payments, 2019–2025

Across 116 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$877
  • AstraZeneca$227
  • Amgen$204
  • Medtronic$121
  • E.r. Squibb & Sons, L.L.C.$75
  • Novartis$70
  • plus $334 from 8 others

What the payments were for

  • Food & beverage$1,87398%
  • Education$342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,907 in reported general payments places this provider in the 50th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$252,505
Medicare patients
514
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide113$289,178
FarxigaDapagliflozin Propanediol268$285,118
LupkynisVoclosporin24$243,127
KerendiaFinerenone116$118,026
JanuviaSitagliptin Phosphate83$109,265
EntrestoSacubitril/Valsartan94$97,353
AuryxiaFerric Citrate42$58,512
OzempicSemaglutide54$49,626
TradjentaLinagliptin27$22,133
LokelmaSodium Zirconium Cyclosilicate34$21,737
Sevelamer Carbonate126$21,527
EliquisApixaban19$18,053
JardianceEmpagliflozin12$17,845
DapagliflozinDapagliflozin Propanediol24$16,525
Valsartan357$11,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$227$306,855302 claims
Fresenius USA Marketing, Inc.Velphoro$877$289,178113 claims
Aurinia Pharma U.S., Inc.Lupkynis$33$243,12724 claims
BayerKerendia$57$118,026116 claims
NovartisEntresto$70$97,35394 claims
Novo NordiskOzempic$48$49,62654 claims
Boehringer IngelheimTradjenta, Jardiance$20$39,97839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 756 nephrology providers in Florida.

Other nephrology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →